{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:33:46Z","timestamp":1789702426860,"version":"4.0.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The phase 3 SYMPATICO study included an open-label cohort to evaluate first-line ibrutinib plus venetoclax in patients with nonblastoid mantle cell lymphoma (MCL) aged \u226565 years (n = 65) or \u226518 years with a TP53 mutation (TP53m; n = 11). Eligible patients received oral ibrutinib 560 mg once daily and venetoclax (5-week ramp-up to 400 mg once daily) for 2 years, then single-agent ibrutinib 560 mg until disease progression or unacceptable toxicity. In total, 78 patients were enrolled. With a median time on study of 40.5 months, the complete response (CR) rate was 69% (95% confidence interval [CI], 58-79), and the overall response rate was 95% (95% CI, 87-99). The median duration of response was 37.1 months (95% CI, 30.3 to not estimable [NE]). The median progression-free survival (mPFS) was 40.2 months (95% CI, 29.4 to NE); median overall survival (OS) was not reached (3-year OS rate, 79% [95% CI, 68-86]). In patients aged \u226565 years, CR rates were 76% (no TP53m) and 44% (with TP53m), mPFS was 40.2 and 22.0 months, and 3-year OS was 85% and 66%, respectively. In adult patients aged &amp;lt;65 years (with TP53m), the CR rate was 73%, mPFS was 15.4 months, and 3-year OS was 73%. The most common treatment-emergent adverse events were diarrhea (49%), fatigue (37%), neutropenia (35%), and COVID-19 (32%). First-line ibrutinib plus venetoclax showed promising efficacy, with high CR rates and durable remissions, in patients with previously untreated nonblastoid MCL and may be an option for patients aged \u226565 years or patients of any age with TP53m. The trial was registered at www.clinicaltrials.gov as NCT03112174.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032833","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:25:55Z","timestamp":1784226355000},"page":"1547-1558","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients \u226565 years old or with\n                    <i>TP53<\/i>\n                    mutations"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"2Hematologic Malignancies, The University of Kansas Cancer Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wrobel","sequence":"additional","affiliation":[{"name":"3Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroc\u0142aw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"4General University Hospital in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[{"name":"54th Department of Internal Medicine\u2013Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Demirkan","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Dokuz Eyl\u00fcl University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0387-3993","authenticated-orcid":false,"given":"Panayiotis","family":"Panayiotidis","sequence":"additional","affiliation":[{"name":"7General Hospital of Athens Laiko, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"8Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"9Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Margaret","family":"Keating","sequence":"additional","affiliation":[{"name":"10Division of Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"11Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5513-5880","authenticated-orcid":false,"given":"Mikl\u00f3s","family":"Egyed","sequence":"additional","affiliation":[{"name":"12Somogy County M\u00f3r Kaposi General Hospital, Kaposv\u00e1r, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"13Peter MacCallum Cancer Centre, Alfred Health and Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"14Jewish General Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[{"name":"15AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lin","sequence":"additional","affiliation":[{"name":"15AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dean","sequence":"additional","affiliation":[{"name":"15AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5247-7896","authenticated-orcid":false,"given":"Jutta K.","family":"Neuenburg","sequence":"additional","affiliation":[{"name":"15AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"von Keudell","sequence":"additional","affiliation":[{"name":"16Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"26","key":"2026091711213280200_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"10044","key":"2026091711213280200_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"2026091711213280200_bib3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091711213280200_bib4","doi-asserted-by":"crossref","first-page":"103212","DOI":"10.1016\/j.critrevonc.2020.103212","article-title":"Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review","volume":"158","author":"Monga","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10441","key":"2026091711213280200_bib5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"2026091711213280200_bib6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"2026091711213280200_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: a British Society for Haematology guideline","volume":"204","author":"Eyre","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"2026091711213280200_bib8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10514","key":"2026091711213280200_bib9","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","article-title":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","volume":"406","author":"Lewis","year":"2025","journal-title":"Lancet"},{"issue":"16","key":"2026091711213280200_bib10","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2026091711213280200_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","article-title":"The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target","volume":"146","author":"Cheung","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2026091711213280200_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2026091711213280200_bib13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026091711213280200_bib14","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"10020","key":"2026091711213280200_bib15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"2026091711213280200_bib16","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2026091711213280200_bib17","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"17","key":"2026091711213280200_bib18","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026091711213280200_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026091711213280200_bib20","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"21","key":"2026091711213280200_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V124.21.509.509","article-title":"Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199 (GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions","volume":"124","author":"Portell","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2026091711213280200_bib22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"2026091711213280200_bib23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2023023388","article-title":"Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions","volume":"144","author":"Handunnetti","year":"2024","journal-title":"Blood"},{"issue":"13","key":"2026091711213280200_bib24","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2026091711213280200_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","article-title":"Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026091711213280200_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"2026091711213280200_bib27","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/JCO.2025.43.16_suppl.7017","article-title":"Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026091711213280200_bib28","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026091711213280200_bib29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2026091711213280200_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2026091711213280200_bib31","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2026091711213280200_bib32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 Mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2026091711213280200_bib33","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"2026091711213280200_bib34","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.3324\/haematol.2018.194399","article-title":"Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma","volume":"103","author":"Eskelund","year":"2018","journal-title":"Haematologica"},{"key":"2026091711213280200_bib35","first-page":"199","article-title":"TP53 status in mantle cell lymphoma (MCL) - a 10- year single center experience","volume":"4","author":"Elhassadi","year":"2019","journal-title":"Hematol Med Oncol"},{"issue":"12","key":"2026091711213280200_bib36","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026091711213280200_bib37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026091711213280200_bib38","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026091711213280200_bib39","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed long-term follow-up of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2021","journal-title":"Hemasphere"},{"issue":"10","key":"2026091711213280200_bib40","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2026091711213280200_bib41","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"2026091711213280200_bib42","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026091711213280200_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2026091711213280200_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026091711213280200_bib45","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1080\/10428194.2023.2256911","article-title":"Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia","volume":"64","author":"Huntington","year":"2023","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1547\/2588615\/blood_bld-2025-032833-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/12\/1547\/2588615\/blood_bld-2025-032833-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:21:45Z","timestamp":1789658505000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/12\/1547\/569472\/First-line-ibrutinib-plus-venetoclax-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032833","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,17]]},"published":{"date-parts":[[2026,9,17]]}}}